Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.47 Analyst target: $5.03 Upside: 974.56%
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.
See the full interactive analysis & chart →Informational only — not investment advice.